Check the time stamp on this data. Updated AI-Generated Signals for Viking Therapeutics Inc. (VKTX) available here: VKTX.

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today's highest-growth healthcare markets: weight loss drugs. The biotech ...

With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $64.63 which represents a slight increase of $1.49 or 2.36% from the prior close of $63.14. The stock opened at ...

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price ...

Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...